Condition
Job's Syndrome
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
80.0%-7% vs avg
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
80.0%
-6.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results80% success
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 2 (1)
P 3 (1)
Trial Status
Completed4
Terminated1
Trial Success Rate
80.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT00033982Phase 3Completed
Posaconazole to Treat Invasive Fungal Infections
NCT00260702Phase 1Completed
Omalizumab to Treat Hyper-IgE (Job's) Syndrome
NCT00527878Phase 2TerminatedPrimary
Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome
NCT00005933Completed
Learning and Behavior Problems in Children With Chronic Granulomatous Disease and Related Disorders
NCT00001515Phase 1Completed
Diagnostic Effectiveness of Virtual Bronchoscopy
Showing all 5 trials